Several recent studies have shown that HDAC inhibition with SAHA, trichostatin A, or valproic acid, reduced ROS production in experimental diabetes, pulmonary hypertension, and atherosclerosis, through inhibitions of NOX1/2/4/5 expression via epigenetically regulating chromatin accessibility29–32. The gene discussed is HDAC9; the disease is atherosclerosis.